Zacks Research Predicts Reduced Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Zacks Research lowered their Q3 2025 earnings per share estimates for Zimmer Biomet in a research report issued on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $1.95 for the quarter, down from their prior estimate of $1.98. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $8.48 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.20 EPS and FY2026 earnings at $9.13 EPS.

Other research analysts have also issued research reports about the company. Raymond James dropped their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Oppenheimer dropped their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Wells Fargo & Company raised their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. TD Cowen dropped their target price on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a report on Friday, September 6th. Finally, Wolfe Research started coverage on Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Trading Up 1.2 %

Shares of Zimmer Biomet stock opened at $112.02 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet has a 52 week low of $101.47 and a 52 week high of $133.90. The stock has a 50 day moving average price of $107.18 and a two-hundred day moving average price of $109.50. The stock has a market capitalization of $22.30 billion, a PE ratio of 21.30, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter last year, the firm posted $1.65 earnings per share. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds have recently made changes to their positions in the stock. Kennedy Capital Management LLC purchased a new position in Zimmer Biomet during the first quarter worth about $1,837,000. California State Teachers Retirement System grew its position in Zimmer Biomet by 1.4% during the first quarter. California State Teachers Retirement System now owns 339,631 shares of the medical equipment provider’s stock worth $44,824,000 after buying an additional 4,751 shares in the last quarter. iA Global Asset Management Inc. bought a new stake in Zimmer Biomet during the first quarter worth about $1,243,000. Plato Investment Management Ltd lifted its stake in Zimmer Biomet by 839.4% during the first quarter. Plato Investment Management Ltd now owns 930 shares of the medical equipment provider’s stock worth $123,000 after purchasing an additional 831 shares during the last quarter. Finally, Wahed Invest LLC lifted its stake in Zimmer Biomet by 19.5% during the first quarter. Wahed Invest LLC now owns 4,120 shares of the medical equipment provider’s stock worth $544,000 after purchasing an additional 671 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.